Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has completed its agreement with Perrigo Company for the divestment of US rights to Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn’s disease, an area of medicine outside AstraZeneca’s strategic focus.
Subscribe to our email newsletter
Upon completion of the agreement, Perrigo paid AstraZeneca $380m to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals.
The transaction does not include the transfer of any AstraZeneca employees or facilities.
The agreement completes the global divestment of Entocort, following the agreement entered into in July 2015 with Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights to Entocort outside the US.
The divestment further emphasises AstraZeneca’s strategic focus on three main therapy areas. The transaction does not impact AstraZeneca’s financial guidance for 2015.